Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Recipient : Stemirna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Stemirna COVID-19 Vaccine Candidate Obtains Clinical Trial Approval in China
Details : The potential vaccine, which Stemirna has started working on since January last year, is based on messenger RNA (mRNA) technology, Tibet Rhodiola Pharma, which is jointly developing the candidate with Stemirna.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 01, 2021
Lead Product(s) : mRNA COVID-19 Vaccine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Stemirna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gam-COVID-Vac,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
China's Rhodiola Set to Sell and Test Russia's Sputnik-V Vaccine
Details : Tibet Rhodiola Pharmaceutical plans to conduct early and mid-stage trials of the Sputnik V vaccine in China and final-stage trials overseas, although the trials are yet to be approved by regulators.
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Gam-COVID-Vac,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
